Faslodex

Leer esta página en español


Faslodex (chemical name: fulvestrant) is approved by the U.S. Food and Drug Administration to treat:

  • postmenopausal women diagnosed with advanced (metastatic) hormone-receptor-positive breast cancer that has stopped responding to other hormonal therapy medicines, such as tamoxifen

Faslodex is the only ERD available to treat breast cancer.

Faslodex won't work on hormone-receptor-negative breast cancer.

Faslodex is liquid that is given once a month as an injection into a muscle, usually at your doctor's office. Women usually get Faslodex as long as it is effectively treating the cancer.

Benefits of Faslodex

Research has shown that Faslodex works as well as or better than Arimidex (chemical name: anastrozole), an aromatase inhibitor, in slowing or stopping the growth of metastatic (breast cancer that has spread to other parts of the body), hormone-receptor-positive breast cancer in postmenopausal women after tamoxifen has stopped working.

Side effects of Faslodex

The most common side effects of Faslodex are:

Some women may have other side effects while getting Faslodex:

Does insurance cover Faslodex?

Costs for Faslodex can vary. If you have health insurance, check with your insurance company to see if and how much of the cost of Faslodex is covered. If you don't have health insurance or your insurance doesn't cover the cost of Faslodex, ask your doctor or nurse about programs in your area that may be able to help.

AstraZeneca, the company that makes Faslodex, offers the AZ Cancer Support Network, which can help you learn about prescription programs. In the United States, call 1-866-992-9276, or visit the AstraZeneca patient prescription assistance programs page.

You can also read the Breastcancer.org Paying for Your Care section for information on additional types of financial assistance and cost-lowering tips.

To connect with others taking Faslodex, ask questions, get answers and support, visit the Breastcancer.org Discussion Board thread Faslodex Girls Thread 2014.

Was this resource helpful?

Yes No
Evergreen-donate
Back to Top